Overview Evaluation of the Bioavailability of Pramlintide Status: Completed Trial end date: 2002-12-01 Target enrollment: Participant gender: Summary This is a randomized, open-label, crossover study to examine the bioavailability of pramlintide in normal weight and overweight subjects with type 1 and type 2 diabetes mellitus using insulin. Phase: Phase 2 Details Lead Sponsor: AstraZenecaTreatments: Islet Amyloid PolypeptidePramlintide